RNS Number : 9758M
ValiRx PLC
17 January 2023

17 January 2023

ValiRx PLC

("ValiRx" or the "Company")

Posting of Circular and Notice of General Meeting

London, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to confirm that, further to the announcement made on 13 January 2023, regarding the Fundraising, a circular (the "**Circular**"), including the Notice of General Meeting and a Form of Proxy was posted yesterday to shareholders.

The General Meeting will be held at the offices of DAC Beachcroft LLP, 25 Walbrook, London EC4N 8AF at 11.00 a.m. on 2 February 2023.

A copy of the Circular will shortly be available to download from the Company's website at www.valirx.com/aim-rule-26 .

Unless otherwise defined, all capitalised terms used but not defined in this announcement shall have the meaning given to them in the Circular.

	2023
Announcement of the Fundraising	13 January
Latest time and date for applications under the Broker Offer (if not closed beforehand)	5.00 p.m. on 16 January
Latest date of publication and posting of this document & the Form of Proxy	17 January
First Admission and dealings in the Placing Shares expected to commence on AIM	8.00 a.m. on or around 19 January
Latest time and date for receipt of proxy forms	11.00 a.m. on 31 January
General Meeting	11.00 a.m. on 2 February
Announcement of the results of the General Meeting	2 February
Second Admission and dealings in the Broker Offer Shares expected to commence on AIM	8.00 a.m. on or around 6 February
Expected date for CREST accounts to be credited for Broker Offer Shares to be held in uncertificated form	6 February
Despatch of definitive share certificates in respect of the Broker Offer Shares to be held in certificated form, if applicable	within 10 business days of Second Admission

The expected timetable relating to the Fundraising is set out below.

1. Each of the times and dates above are indicative only and if any of the details contained in the timetable above should change, the revised times and dates will be notified to Shareholders by means of an announcement through a Regulatory Information Service.

2. All of the above times refer to London time unless otherwise stated.

3. All events listed in the above timetable related to the Second Admission and the Broker Offer are conditional on the passing at the General Meeting of the Fundraising Resolutions to provide the relevant authorities.

The Directors of the Company take responsibility for this announcement.

For more information, please contact:

ValiRx plc Dr Suzanne Dilly, CEO	**Tel: +44 (0) 2476 796496** **www.valirx.com** Suzanne.Dilly@valirx.com
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray/Jo Turner/Ludovico Lazzaretti	**Tel: +44 (0) 20 7213 0880**
Cenkos Securities plc (Joint Broker) Russell Kerr/Michael Johnson (Sales) Callum Davidson/Giles Balleny (Corporate Finance)	**Tel: +44 (0) 20 7397 8900**
Turner Pope Investments (Joint Broker) James Pope / Andy Thacker	**Tel: +44 (0) 20 3657 0050**

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOGEANFXFFPDEEA